Vistagen Therapeutics Inc
VTGN0.728USD
+0.015+2.08%
Close 12/24, 16:00（ET）Quotes delayed by 15 min
28.31MMarket Cap
LossP/E TTM
More Details of Vistagen Therapeutics Inc Company
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
Vistagen Therapeutics Inc Info
Ticker SymbolVTGN
Company nameVistagen Therapeutics Inc
IPO dateOct 18, 2010
CEOSingh (Shawn K)
Number of employees56
Security typeOrdinary Share
Fiscal year-endOct 18
Address343 Allerton Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16505773600
Websitehttps://www.vistagen.com/
Ticker SymbolVTGN
IPO dateOct 18, 2010
CEOSingh (Shawn K)
Company Executives of Vistagen Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Shawn K. Singh, J.D.
Mr. Shawn K. Singh, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
38.90K
--
Mr. Joshua S Prince
Mr. Joshua S Prince
Chief Operating Officer
Chief Operating Officer
10.86K
--
Mr. Jon S. Saxe, J.D.
Mr. Jon S. Saxe, J.D.
Independent Director
Independent Director
1.86K
--
Mr. Reid G. Adler, J.D.
Mr. Reid G. Adler, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Mary L. Rotunno
Ms. Mary L. Rotunno
Independent Director
Independent Director
--
--
Dr. Joanne Curley, Ph.D.
Dr. Joanne Curley, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elissa Cote
Ms. Elissa Cote
Chief Corporate Development Officer
Chief Corporate Development Officer
--
--
Ms. Ann Michelle Cunningham
Ms. Ann Michelle Cunningham
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Mark A. Mcpartland
Mr. Mark A. Mcpartland
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Shawn K. Singh, J.D.
Mr. Shawn K. Singh, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
38.90K
--
Mr. Joshua S Prince
Mr. Joshua S Prince
Chief Operating Officer
Chief Operating Officer
10.86K
--
Mr. Jon S. Saxe, J.D.
Mr. Jon S. Saxe, J.D.
Independent Director
Independent Director
1.86K
--
Mr. Reid G. Adler, J.D.
Mr. Reid G. Adler, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Mary L. Rotunno
Ms. Mary L. Rotunno
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
10.55%
OrbiMed Advisors, LLC
7.75%
TCG Crossover Management, LLC
6.78%
Nantahala Capital Management, LLC
5.01%
StemPoint Capital LP
4.74%
Other
65.18%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
10.55%
OrbiMed Advisors, LLC
7.75%
TCG Crossover Management, LLC
6.78%
Nantahala Capital Management, LLC
5.01%
StemPoint Capital LP
4.74%
Other
65.18%
Shareholder Types
Shareholders
Proportion
Investment Advisor
19.38%
Hedge Fund
16.31%
Investment Advisor/Hedge Fund
12.37%
Private Equity
7.75%
Research Firm
1.88%
Individual Investor
0.26%
Venture Capital
0.18%
Other
41.87%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
105
18.63M
62.39%
-1.74M
2025Q2
119
15.55M
52.09%
-4.48M
2025Q1
178
15.52M
53.23%
-4.54M
2024Q4
189
15.27M
53.10%
-1.38M
2024Q3
188
15.00M
55.60%
-3.08M
2024Q2
215
16.08M
59.60%
-5.25M
2024Q1
231
17.00M
63.09%
-4.65M
2023Q4
242
17.28M
64.17%
+1.95M
2023Q3
236
3.11M
33.43%
-2.83M
2023Q2
238
1.09M
13.89%
-3.94M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
4.17M
13.95%
+4.17M
--
Aug 29, 2025
TCG Crossover Management, LLC
2.68M
8.96%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
1.98M
6.63%
--
--
Jun 30, 2025
StemPoint Capital LP
1.80M
6.02%
+46.70K
+2.67%
Jun 30, 2025
The Vanguard Group, Inc.
1.76M
5.89%
-200.53K
-10.23%
Jun 30, 2025
Commodore Capital LP
1.57M
5.27%
--
--
Jun 30, 2025
Ikarian Capital LLC
601.70K
2.02%
--
--
Jun 30, 2025
Two Sigma Investments, LP
115.28K
0.39%
-7.96K
-6.46%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
6%
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Neuroscience and Healthcare ETF
0%
AdvisorShares Psychedelics ETF
Proportion6%
iShares Micro-Cap ETF
Proportion0.02%
Avantis US Small Cap Equity ETF
Proportion0.01%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Neuroscience and Healthcare ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Date
Type
Ratio
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
FAQs
Who are the top five shareholders of Vistagen Therapeutics Inc?
The top five shareholders of Vistagen Therapeutics Inc are:
Janus Henderson Investors holds 4.17M shares, accounting for 13.95% of the total shares.
TCG Crossover Management, LLC holds 2.68M shares, accounting for 8.96% of the total shares.
Nantahala Capital Management, LLC holds 1.98M shares, accounting for 6.63% of the total shares.
StemPoint Capital LP holds 1.80M shares, accounting for 6.02% of the total shares.
The Vanguard Group, Inc. holds 1.76M shares, accounting for 5.89% of the total shares.
Janus Henderson Investors holds 4.17M shares, accounting for 13.95% of the total shares.
TCG Crossover Management, LLC holds 2.68M shares, accounting for 8.96% of the total shares.
Nantahala Capital Management, LLC holds 1.98M shares, accounting for 6.63% of the total shares.
StemPoint Capital LP holds 1.80M shares, accounting for 6.02% of the total shares.
The Vanguard Group, Inc. holds 1.76M shares, accounting for 5.89% of the total shares.
What are the top three shareholder types of Vistagen Therapeutics Inc?
The top three shareholder types of Vistagen Therapeutics Inc are:
Janus Henderson Investors
OrbiMed Advisors, LLC
TCG Crossover Management, LLC
Janus Henderson Investors
OrbiMed Advisors, LLC
TCG Crossover Management, LLC
How many institutions hold shares of Vistagen Therapeutics Inc (VTGN)?
As of 2025Q3, 105 institutions hold shares of Vistagen Therapeutics Inc, with a combined market value of approximately 18.63M, accounting for 62.39% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 10.30%.
What is the biggest source of revenue for Vistagen Therapeutics Inc?
In --, the -- business generated the highest revenue for Vistagen Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
